Assembly Biosciences Key Fundamental Indicators
| ASMB Stock | USD 26.66 0.57 2.18% |
As of the 15th of February 2026, Assembly Biosciences shows the Standard Deviation of 3.87, mean deviation of 2.93, and Risk Adjusted Performance of (0.03). Assembly Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Assembly Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.1594 | Revenue |
Assembly | Select Account or Indicator | Build AI portfolio with Assembly Stock |
Assembly Biosciences Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assembly Biosciences Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assembly Biosciences Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assembly Biosciences Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assembly Fundamental Market Drivers
Assembly Upcoming Events
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Assembly Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Assembly Biosciences is extremely important. It helps to project a fair market value of Assembly Stock properly, considering its historical fundamentals such as Current Valuation. Since Assembly Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Assembly Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Assembly Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Assembly Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.60) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Assembly Biosciences's market price often diverges from its book value, the accounting figure shown on Assembly's balance sheet. Smart investors calculate Assembly Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Assembly Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Assembly Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assembly Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Assembly Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Assembly Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Assembly Biosciences.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Assembly Biosciences on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Assembly Biosciences or generate 0.0% return on investment in Assembly Biosciences over 90 days. Assembly Biosciences is related to or competes with Zura Bio, Foghorn Therapeutics, Immuneering Corp, Sagimet Biosciences, Enanta Pharmaceuticals, Aardvark Therapeutics, and Nautilus Biotechnology. Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for th... More
Assembly Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Assembly Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Assembly Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (6.65) | |||
| Potential Upside | 5.88 |
Assembly Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Assembly Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Assembly Biosciences' standard deviation. In reality, there are many statistical measures that can use Assembly Biosciences historical prices to predict the future Assembly Biosciences' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.18) |
Assembly Biosciences February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.17) | |||
| Mean Deviation | 2.93 | |||
| Coefficient Of Variation | (1,885) | |||
| Standard Deviation | 3.87 | |||
| Variance | 14.96 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.18) | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (6.65) | |||
| Potential Upside | 5.88 | |||
| Skewness | (0.20) | |||
| Kurtosis | 0.5544 |
Assembly Biosciences Backtested Returns
Assembly Biosciences secures Sharpe Ratio (or Efficiency) of -0.11, which signifies that the company had a -0.11 % return per unit of risk over the last 3 months. Assembly Biosciences exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Assembly Biosciences' Risk Adjusted Performance of (0.03), standard deviation of 3.87, and Mean Deviation of 2.93 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.2, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Assembly Biosciences will likely underperform. At this point, Assembly Biosciences has a negative expected return of -0.43%. Please make sure to confirm Assembly Biosciences' kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Assembly Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.60 |
Good predictability
Assembly Biosciences has good predictability. Overlapping area represents the amount of predictability between Assembly Biosciences time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Assembly Biosciences price movement. The serial correlation of 0.6 indicates that roughly 60.0% of current Assembly Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.6 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 5.63 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Assembly Biosciences has a Current Valuation of 191.88 M. This is 98.66% lower than that of the Biotechnology sector and 95.87% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.85% higher than that of the company.
Assembly Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Assembly Biosciences's current stock value. Our valuation model uses many indicators to compare Assembly Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Assembly Biosciences competition to find correlations between indicators driving Assembly Biosciences's intrinsic value. More Info.Assembly Biosciences is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . At present, Assembly Biosciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Assembly Biosciences' earnings, one of the primary drivers of an investment's value.Assembly Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Assembly Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Assembly Biosciences could also be used in its relative valuation, which is a method of valuing Assembly Biosciences by comparing valuation metrics of similar companies.Assembly Biosciences is currently under evaluation in current valuation category among its peers.
Assembly Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Assembly Biosciences from analyzing Assembly Biosciences' financial statements. These drivers represent accounts that assess Assembly Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Assembly Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 288.1M | 100.8M | 45.0M | 94.8M | 85.3M | 168.1M | |
| Enterprise Value | 238.8M | 61.7M | 27.5M | 59.5M | 53.5M | 50.9M |
Assembly Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Assembly Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Assembly Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Assembly Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.01) % | ||||
| Current Valuation | 191.88 M | ||||
| Shares Outstanding | 15.82 M | ||||
| Shares Owned By Insiders | 32.29 % | ||||
| Shares Owned By Institutions | 54.15 % | ||||
| Number Of Shares Shorted | 1.54 M | ||||
| Price To Earning | (10.58) X | ||||
| Price To Book | 2.31 X | ||||
| Price To Sales | 11.34 X | ||||
| Revenue | 28.52 M | ||||
| Gross Profit | (24.65 M) | ||||
| EBITDA | (45.29 M) | ||||
| Net Income | (40.18 M) | ||||
| Cash And Equivalents | 116.69 M | ||||
| Cash Per Share | 2.41 X | ||||
| Total Debt | 3.09 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.31 X | ||||
| Book Value Per Share | 11.55 X | ||||
| Cash Flow From Operations | (51.12 M) | ||||
| Short Ratio | 14.16 X | ||||
| Earnings Per Share | (4.60) X | ||||
| Target Price | 47.75 | ||||
| Number Of Employees | 73 | ||||
| Beta | 1.15 | ||||
| Market Capitalization | 421.68 M | ||||
| Total Asset | 119.17 M | ||||
| Retained Earnings | (825.92 M) | ||||
| Working Capital | 67.7 M | ||||
| Current Asset | 68.37 M | ||||
| Current Liabilities | 3.4 M | ||||
| Net Asset | 119.17 M |
About Assembly Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Assembly Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assembly Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assembly Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 43.3 M | 45.4 M | |
| Total Revenue | 32.8 M | 34.4 M | |
| Cost Of Revenue | 148.3 K | 140.9 K | |
| Stock Based Compensation To Revenue | 0.13 | 0.12 | |
| Sales General And Administrative To Revenue | 0.57 | 0.54 | |
| Research And Ddevelopement To Revenue | 1.77 | 1.68 | |
| Revenue Per Share | 5.46 | 6.93 | |
| Ebit Per Revenue | (1.83) | (1.92) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:Check out For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Assembly Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.60) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Assembly Biosciences's market price often diverges from its book value, the accounting figure shown on Assembly's balance sheet. Smart investors calculate Assembly Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Assembly Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Assembly Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assembly Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.